-
Synthetic Biology, Genomics & Advanced Therapeutics3 weeks agoViruses That Board CAR Cells: A Modular Push Against Solid Tumors
A new review proposes co-designing oncolytic viruses and CAR-T or CAR-NK cells as a modular, self-amplifying therapeutic system to overcome the barriers that limit cell therapy...
-
Synthetic Biology, Genomics & Advanced Therapeutics3 weeks agoBioSpace 40 Under 40 winners make their mark on biopharma
40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million...
-
Synthetic Biology, Genomics & Advanced Therapeutics3 weeks agoFlicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research
Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD,...
-
Synthetic Biology, Genomics & Advanced Therapeutics3 weeks agoWeighing the risks of CAR T in autoimmune disease as Kyverna nears market
Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoNovartis turns to mRNA-encoded engagers for B cell depletion
BIOCENTURY | DEALSNOVARTIS TURNS TO MRNA-ENCODED ENGAGERS FOR B CELL DEPLETIONPharma pays $575M up front for Abogen’s CD3 x CD19 engager to treat autoimmune diseases
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoSarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoNovartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoSTAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoBlueRock Therapeutics’ Investigational Cell Therapy Lemiretprocel (OpCT-001) for Primary Photoreceptor Diseases Granted Orphan Drug Designations by FDA and EMA
Berlin, Germany, and Cambridge, MA, USA, September 30, 2026 – Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoAnti-fibrotic drug could be repurposed to control cell communication
An experimental antifibrotic compound can dramatically alter how cells release the microscopic packages they use to communicate, according to new research from the University of Surrey....
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
